Skip to main content

Closed

CRSP: CRISPR Therapeutics AG Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-90.0% / yr

Operating margin-13408.3%

ROIC-21.1%

Financially safe

Stretched

Debt / equity0.43×

Interest coverage0.0×

Current ratio17.96×

CRISPR Therapeutics AG

CRSPNASDAQ Global Market·USD·Closed

CRISPR Therapeutics AG

CRSPNASDAQ·USD·Closed

$47.99

−0.93%

$47.99

−$0.45 (0.93%)

52W Range

11thpctl

Volume

0.59×avg

Mkt Cap

4.63BUSD

P/E

-7.7TTM

Div Yield

–ann

52W Range

11thpctl

Volume

0.59×avg

Market Cap

4.63BUSD

P/E Ratio

-7.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings